Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...
The Phase 1 trial ANQUR, now testing two new doses of the ALS therapy QRL-201, is enrolling patients at 12 sites in Canada and across Europe.
Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...
1h
On Monday, PTC Therapeutics, Inc. (NASDAQ:PTCT) signed an exclusive global license and collaboration agreement with Novartis ...
The groundbreaking physicist not only made a splash by discovering that black holes emit radiation, but also as a pop-culture ...
Scientists studied 188 people related to someone with ALS caused by a C9ORF72 mutation to identify markers of disease risk in ...
The Food and Drug Administration (FDA) has not approved stem cell therapy for amyotrophic lateral sclerosis (ALS). However, people could participate in clinical trials involving this ALS treatment.
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...
Vinci Vogue Anžlovar, author of a 1991 hit comedy that was the first feature film released after Slovenia became independent, ...
MRI is a diagnostic test that doctors use to diagnose and track the progress of amyotrophic lateral sclerosis (ALS). ALS is a progressive disease that damages nerve cells in the brain and spinal cord.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback